Mikronos Biomedical

Uncontrolled bleeding in trauma situations such as traffic and work accidents is the leading cause of potentially preventable deaths among trauma patients. Approximately one third of all trauma patients with bleeding have a coagulation disorder. Each year, 2.5 million people worldwide die because of this. Conventional (PT / INR and aPTT) tests recommended for the detection of post-traumatic coagulation problems are insufficient to identify coagulation problems in critically ill patients, as they only test the onset of coagulation and viscoelastic test results should be used for more detailed information. However, these tests are expensive, require trained personnel, and results take time. Our microfluidics based system; rapidly measures the viscoelastic properties of the patient’s blood without the need for sample preparation making it possible to evaluate coagulation disorders in trauma patients in detail, and offers treatment advice using analysis algorithms. Our system reduces system costs by not needing regular calibration and expert personnel. Moreover, since it works with low volume samples, it also reduces chemical consumption costs, and with its artificial intelligence-supported software, it saves time in the intervention of the patient and thus reduces the time spent in intensive care and improves patient outcome.

Company’s Keywords:

blood coagulation analysis, medical device, point of care